There was no difference between the groups for glucose ranges >150, ≥180, or ≥250 mg/dL.
There was no significant difference of initial rate of xylose release between the groups in untreated (xylose, F 3,12) = 0.62, P = 0.62), but there was a significant difference between groups for initial rate of glucose release (glucose, F 3,12) = 11.22, P < 0.05).
At the end of the 6-month intervention, there were no significant differences between the two groups for glucose, insulin, systolic and diastolic blood pressure, HDL-C, or triglycerides.
The F test for ANOVA in the case of continuous variables or χ tests in the case of proportions were performed to test for differences between groups of glucose status.
Therefore, it was not possible to compare between groups for insulin requirements and glucose levels.
A total of 83 consecutive patients were allocated to the normal, median, or high admission plasma glucose group for glucose levels of < 7.8 mmol/L, between 7.8 and 11.1 mmol/L, or ≥11.1 mmol/L, respectively.
Moreover, by ensuring similar glucose lowering treatments for all patients at baseline, the run-in period served to minimise any confounding effect of chance differences between groups in previous glucose lowering therapies.
There were no significant differences between the groups for insulin, fasting glucose, fructosamine, proinsulin, C-peptide, and HOMA-IR (Table 1).
The outcomes were comparisons between treatment groups for the plasma glucose, insulin, triglyceride, chylomicron triglyceride, hsCRP, TNF-α, interleukin-6, methylglyoxal and 3-deoxyglucosone concentrations at each time point.
Similar results were also reported between the two groups for fasting plasma glucose and reductions in mean seven-point glucose profiles, although the pattern of change for postprandial glucose excursions was slightly different between the two treatment groups (Fig. 6).
